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Second-Hand Exposure of Staff Administering Vaporised Cannabinoid
Products to Patients in a Hospital Setting
Abstract

Background In many health settings, administration of medicinal cannabis poses significant implementation
barriers including drug storage and safety for administering staff and surrounding patients. Different modes of
administration also provide different yet potentially significant issues. One route that has become of clinical
interest owing to the rapid onset of action and patient control of the inhaled amount (via breath timing and
depth) is that of vaporisation of cannabinoid products. Although requiring a registered therapeutic device for
administration, this is a relatively safe method of intrapulmonary administration that may be particularly
useful for patients with difficulty swallowing, and for those in whom higher concentrations of cannabinoids
are needed quickly. A particular concern expressed to researchers undertaking clinical trials in the hospital is
that other patients, nurses, and clinical or research staff may be exposed to second-hand vapours in the course
of administering vaporised products to patients. Objective The objective of this study was to take samples
from two research staff involved in administering vaporised D9-tetrahydrocannabinol to participants in a
clinical trial, to examine and quantitate cannabinoid presence. Methods Blood samples from two research staff
were taken during the exposure period for three participants (cannabis users) over the course of
approximately 2.5 h and analysed using tandem mass spectrometry. Results Blood samples taken over a
vaporised period revealed exposure below the limit of detection for D9-tetrahydrocannabinol and two
metabolites, using tandem mass spectrometry analytical methods. Conclusions These results are reassuring
for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to
ethics committees wishing to quantify risk.
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Abstract

Background In many health settings, administration of medicinal cannabis use poses significant implementation
barriers including drug storage and safety for administering staff and surrounding patients. Different modes of
administration also provide different yet potentially significant issues. One route that has become of clinical
interest due to rapid onset of action and patient control of inhaled amount (via breath timing and depth) is that of
vaporisation of cannabinoid products. Although requiring a registered therapeutic device for administration, this
is a relatively safe method of intrapulmonary administration which may be particularly useful for patients with
difficulty swallowing, and for those in whom higher concentrations of cannabinoids are needed quickly. A
particular concern expressed to researchers undertaking clinical trials in the hospital is that other patients,
nurses, clinical or research staff may be exposed to secondhand vapours in the course of administering
vaporised products to patients. We elected to take samples from two research staff involved in administering
vaporised 9-tetrahydrocannabinol to participants in a clinical trial, to examine and quantitate
cannabinoid presence.

Methods Blood samples from two research staff were taken during the exposure period for three participants
(cannabis users) over the course of approximately 2.5 hours and analysed using tandem mass spectroscopy.

Results Blood samples taken over a vaporised period revealed exposure below the limit of detection for 9tetrahydrocannabinol and two metabolites, using tandem mass spectroscopy analytical methods.

Conclusions These results are reassuring for hospital and clinical trials practices with staff administering
vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.

Key findings: Staff administering vaporised cannabinoid products in a clinical setting do not appear to be at
risk from secondhand exposure.
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1 Introduction
Medicinal cannabis use, whilst now legal in many jurisdictions, remains a topic of great controversy. For its
consideration for use in mainstream medical treatment pathways as a ‘therapeutic good’, or in clinical trials in
hospital settings, it is crucial to understand the acceptability and side effects of the route of administration for
different products and dosing regimens. One route that has become of clinical interest is that of vaporisation of
cannabinoid products. Although requiring a registered therapeutic device for administration, this is a relatively
safe method of intrapulmonary administration that avoids risks associated with smoking and the formation of
pyrolytic toxic compounds as it does not involve combustion [1]. It is also less likely to be associated with the
cultural and societal assumptions linked with recreational cannabis use. The vaporisation route of administration
may be particularly useful for patients with difficulty swallowing and for those in whom higher concentrations
of cannabinoids are needed quickly. Peak plasma 9-tetrahydrocannabinol (THC) concentrations are reached
within minutes of inhalation and have a rapid distribution phase [2-4].

The concern that other patients, nurses, clinical or research staff may be exposed to secondhand vapours in the
course of administering vaporised products to patients may limit the uptake of this form of treatment. Similar
concerns have been raised for other medications, such as potential antimicrobial resistance development from
exposure to nebulised antibiotics [5]. Previous well-controlled studies have determined that secondhand
exposure to cannabis smoke may produce positive blood and urine test results and minor drug effects in nonsmokers only under extreme conditions: non-smokers being in very close proximity to smokers using mediumhigh potency cannabis ad libitum in a small unventilated area for one hour and using sensitive urinary assays
with low cutoff criteria [6,7]. Under extreme exposure conditions to inhaled cannabis smoke within a motor
vehicle, no THC was detected in the oral fluid of those passively exposed [8], noting limitations with the
interpretation of salivary cannabinoid assays in detecting time of use and overall exposure, reviewed in [9]. No
studies have investigated systemic exposure from secondhand vaporised cannabinoid product use. We used
opportunistic sampling from staff administering vaporised pure THC within a clinical trial in a hospital setting
to examine the likely risk.
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2 Methods
In a clinical trial involving a vaporised ethanolic solution of 6mg THC [ISRCTN24109245] [10] using the
Volcano ‘Digit’ model vaporiser (Storz & Bickel GmbH & Co. Tuttlingen, Germany) set at 230C, two
female clinical research staff gave informed consent to contribute blood samples to ascertain their exposure.
Vaporisation of THC into the balloon and administration of the balloon filled with vapours for inhalation by
trial participants (cannabis users and nonusers) was conducted in a small standard clinical assessment room on a
hospital ward, away from other patients and near to imaging facilities. The approximate size of the room was
3m x 2m. One of the staff (A) administered the balloon to the participant and remained approximately 1m away
from the participant during inhalation and exhalation. The other staff member (B) was positioned inside the
room but closer to the partially opened door, approximately 2m away from the participant. There was no
specific ventilation in the room aside from a standard small air conditioning vent. Participants inhaled and
exhaled on average 6-10 times to empty a balloon, and two balloons were administered. The first contained
vaporised THC, the second placebo (ethanol flavoured air; see [10] for methodology) and participants took on
average 9 minutes to complete inhalation of both balloons (~5-6 minutes for the THC balloon and 3-4 minutes
for the placebo balloon). Four blood samples were collected from staff over the course of approximately 2.5
hours. The first was taken prior to any drug administration. The subsequent three were taken 5 minutes after
each of three participants completed inhalation of the balloons, with participants spaced approximately one hour
apart. Administration to the three participants occurred in the same room following the same procedures. As
such, there was the possibility of cumulative exposure over the course of this approximate 2.5 hour period.

Staff gave 5 ml of blood, collected into EDTA tubes, which were covered with aluminium foil to prevent light
exposure and kept on ice until the end of the day when they were centrifuged at 2000 x g for 10 min at 4C and
the plasma extracted. Plasma samples were stored frozen at -80C and subsequently defrosted for assay by
tandem mass spectroscopy [11]. Plasma (50µl) samples were combined with 100µl of acetonitrile containing
deuterated internal standards. Samples were then vortexed before been centrifuged at 15000xg for 5 mins. The
supernatant was transferred into vials for measurement using liquid chromatography tandem mass spectrometry
(LCMSMS). The instrument was composed of a Shimadzu Nexera2 UHPLC with an SCIEX 6500QTrap, a
Kinetex Biphenyl column using a gradient of acetonitrile and 0.1% formic acid. The limit of quantitation was
0.5 ng/ml for each THC, and the metabolites 11-hydroxy-9-tetrahydrocannabinol (OH-THC) and 11-nor-9-
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carboxy-9-tetrahydrocannabinol (COOH-THC). The limit of detection (LOD) was 0.2 ng/ml for THC, 0.15
ng/ml for OH-THC and 0.25 ng/ml for COOH-THC.

One of the research staff (B) also performed a urinary drug test several hours after these procedures
(ProScreenTM Dip Test; cutoff 50ng/ml). Both staff also performed salivary tests for THC (Oratect IIIB; cutoff
40ng/ml).

3 Results
No cannabinoids were detected in plasma from either staff member (A: BMI 20.1, or B: BMI 20.2) at baseline,
nor, as shown in Table 1, at any of the three timepoints taken 5 minutes after completion of inhalation of THC
vapours by each of three participants spaced one hour apart.

Table 1 Results of LCMSMS analysis of THC and metabolites (ng/ml) in plasma from two staff (A and B)
exposed three times to exhaled vapours over the course of a 2.5 hour period. Samples (1), (2) and (3)
drawn 5 minutes after each of three participants spaced ~1 hour apart were exposed to vaporised THC.
Sample

THC

OH-THC

COOH-THC

A (1)

<LOD

<LOD

<LOD

A (2)

<LOD

<LOD

<LOD

A (3)

<LOD

<LOD

<LOD

B (1)

<LOD

<LOD

<LOD

B (2)

<LOD

<LOD

<LOD

B (3)

<LOD

<LOD

<LOD

LCMSMS: liquid chromatography tandem mass spectrometry; THC: 9-tetrahydrocannabinol; OH-THC: 11hydroxy-9-tetrahydrocannabinol; COOH-THC: 11-nor-9-carboxy-9-tetrahydrocannabinol

The urinary drug test was negative for cannabinoids. The salivary THC tests were both negative.

That the experiment and assays were valid, is evidenced by the quantification of THC and metabolites in the
plasma of two of the THC-exposed male research participants (X and Y) shown in Table 2 (blood was not
successfully drawn from the third participant due to unviable veins). Plasma concentrations in Table 2
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correspond to baseline (pre-drug administration; 1), 5 minutes after inhalation of the two balloons (2), and 1
hour later (3). Participant Y was a heavy cannabis user, explaining cannabinoid concentrations present at
baseline.

Table 2 Results of LCMSMS analysis of THC and metabolites (ng/ml) in plasma from two cannabis users
(X and Y) exposed to vaporised THC. Samples drawn prior to THC administration (1); 5 minutes after
THC administration (2); and one hour later (3).
Sample

THC

OH-THC

COOH-THC

X (1)

<LOD

<LOD

<LOD

X (2)

183.4

1.6

<LOD

X (3)

15.2

1.0

4.9

Y (1)

12.9

3.4

75.6

Y (2)

223.5

4.5

66.1

Y (3)

28.9

6.3

68.3

LCMSMS: liquid chromatography tandem mass spectrometry; THC: 9-tetrahydrocannabinol; OH-THC: 11hydroxy-9-tetrahydrocannabinol; COOH-THC: 11-nor-9-carboxy-9-tetrahydrocannabinol

4 Conclusions
These results suggest that there is little risk of secondhand exposure to clinical or research staff from
administering vaporised THC within a clinical setting. Previous research has suggested that 35% of THC
vapours inhaled are exhaled directly after inhalation [1] and we previously showed that 80% of the THC loaded
into the vaporiser is delivered into the balloon [10]. Overall, this efficiency of delivery method is comparable to
that achieved through a smoking route of cannabis administration [1]. These conditions and the conditions
within which this small study was performed emulate administration of medicinal cannabis on a hospital ward,
without the smoke, and optimised the opportunity to detect cannabinoids in the biological fluids of staff, yet
none were detected. Together with the fact that newer vaporisers e.g. MiniVap (Hermes Medical Engineering)
have less ‘gas escape’ than the one used in this study, these outcomes should reassure researchers of the safety
for staff in administering medicinal cannabis to patients in this setting. Nevertheless, the THC dose utilised in
this study was relatively low (6mg), and while higher doses are also not expected to result in detectable
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cannabinoids in clinical staff exposed under these conditions, replication of these findings with a larger sample
size, more timepoints, alternate vaporisers, and with vaporisation of cannabis plant matter is warranted.
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